HomeApproved Therapies

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment
|
Less than 1 min read
|
Updated:

The MHRA’s conditional approval allows givinostat to be used in patients with DMD who are six years of age and older, and it is applicable to all genetic variants of the condition. This decision follows the U.S. Food and Drug Administration’s (FDA) approval of givinostat earlier this year.

Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).

In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.

This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.

- Follow Us -
DMD Warrior Whatsapp Channel

Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: What is Duvyzat (Givinostat)?]

- Follow Us -
DMDWarrioR Instagram
SourceMHRA
Add DMDWarrior as a preferred Google source to see more of our trusted coverage.

Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

Previous article
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
Next article
SPLICER Gene Editing Tool Holds A Lot of Potential to Treat Duchenne Muscular Dystrophy

LEAVE A REPLY

Please enter your comment!
Please enter your name here


Trending on DMDWarrioR- Duchenne News

Load more

Related Articles

Load more